Curatis

CURN.SWPre-clinical

Curatis is a clinical-stage biopharmaceutical company dedicated to addressing unmet medical needs in rare diseases and oncology. The company's strategy centers on advancing a pipeline of targeted therapeutics through clinical development, supported by its proprietary discovery platform. As a publicly listed entity, Curatis aims to translate its research into meaningful treatments for patients while creating value for shareholders. Its operations are based in Switzerland, positioning it within a leading European biotech hub.

Market Cap

$118.5M

Focus

Biotech

AI Company Overview

Technology Platform

Proprietary drug discovery and development platform focused on identifying novel targets and generating optimized therapeutic candidates for severe diseases.

Funding History

Total raised: $25M

IPO$25MUndisclosedJun 30, 2021

Opportunities

Opportunities include successful clinical data readouts that can drive partnerships or M&A, expansion into adjacent indications for its pipeline assets, and leveraging the Swiss/European biotech ecosystem for talent and collaboration.

Risk Factors

Key risks include clinical trial failures, inability to secure sufficient funding to advance programs, intense competition in target therapeutic areas, and regulatory hurdles that could delay or prevent approval.

Competitive Landscape

Curatis competes with numerous biopharma companies developing therapies for oncology and autoimmune diseases. Its success depends on demonstrating differentiated efficacy, safety, or mechanistic novelty compared to both existing treatments and other candidates in development.